Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancer

Yap, Timothy A.; Macklin-Doherty, Aislinn; Popat, Sanjay

doi:10.1016/j.ejca.2016.10.014

Cited by 38Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchLung Cancer Diagnosis and Treatment

Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancer

Yap, Timothy A., Macklin-Doherty, Aislinn, Popat, Sanjay·2017·European Journal of Cancer

DOI 10.1016/j.ejca.2016.10.014

Open this paper in CoChat — free account

Abstract

The majority of patients with epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) respond to first-line EGFR tyrosine kinase inhibitors (TKIs), but nearly all inevitably acquire resistance and develop disease progression. Conventional practice would be to switch treatments to second-line therapy. However, continuing TKIs beyond progression is becoming increasingly commonplace in patients with indolent, small volume asymptomatic growth, who may potentially continue to derive ongoing clinical benefit and to avoid a 'withdrawal tumour flare'. Nevertheless, there are limitations to our current criteria for assessing disease response, which are based on radiological assessments without considering symptomatic benefit, or the complex molecular and clinical heterogeneity of tumour growth and drug response patterns. In this article, we review the rationale for continuing EGFR inhibitors in patients with EGFR mutant NSCLC beyond disease progression and discuss strategies that have been pursued in the context of molecularly and clinically heterogeneous populations of tumour growth depending on the different clinical scenarios encountered. We discuss the management of systemic disease progression, including continuing EGFR TKIs alone, introducing a drug holiday, or combining TKIs with chemotherapy or other molecularly targeted agents. We also focus on approaches in managing patients with indolent, small volume asymptomatic growth (non-CNS oligometastatic disease progression) and those with oligometastatic EGFR mutant NSCLC with involvement of the central nervous system. We envision future precision medicine strategies through the use of next generation sequencing strategies of serial tumour rebiopsies and circulating plasma DNA to individualise the management for such patients during disease progression.

Integrity signals

Registry

Crossref · 10.1016/j.ejca.2016.10.014

Cites

84 of 84 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Continuation of EGFR TKI treatment beyond radiological progression may help maintain clinical benefit for some patients with acquired resistance to first-line EGFR TKIs.
“continuation of EGFR TKI treatment beyond radiological progression may help maintain clinical benefit for some patients with acquired resistance to first-line EGFR TKIs.”
From Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings (2020) · cites this paper as [110]
Continuation of TKI beyond progression is supported by previous reports of patients with indolent and small-volume progression benefiting from continuation.
“Nevertheless, the practice of continuation of TKI beyond progression is supported by previous reports of patients with indolent and small volume progression benefiting from continuation of TKIs[15, 29].”
From Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR -Mutant NSCLC (2018) · cites this paper as [29]

2 retracted

Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease
Delbaldo, C., Michiels, S., Rolland, E., Syz, N., Soria, J., Chevalier, T. L., & Pignon, J. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004569.pub3 · Cited by 43 · see citing works
Retracted
Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease
Delbaldo, C., Michiels, S., Rolland, E., Syz, N., Soria, J., Chevalier, T. L., & Pignon, J. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004569.pub2 · Cited by 26 · see citing works
Retracted
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486 · see citing works
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368 · see citing works
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261 · see citing works
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525 · see citing works
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489 · see citing works
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496 · see citing works
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338 · see citing works
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090 · see citing works
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Zhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70184-x · Cited by 4,081 · see citing works
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964 · see citing works
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · see citing works
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
Sequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2806 · Cited by 3,228 · see citing works
Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials
Non-small Cell Lung Cancer Collaborative Group (1995) · BMJ · doi:10.1136/bmj.311.7010.899 · Cited by 3,039 · see citing works
Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials
Villalba, J. B. (1996) · Lung Cancer · doi:10.1016/0169-5002(96)85918-6 · Cited by 2,510 · see citing works
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373 · see citing works
Hepatobiliary Cancers
Benson, A. B., Abrams, T. A., Ben‐Josef, E., Bloomston, M., Botha, J. F., Clary, B. M., Covey, A. M., Curley, S. A., D'Angelica, M. I., Davila, R., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0027 · Cited by 2,271 · see citing works
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
Jänne, P. A., Yang, J. C.-H., Kim, D.-W., Planchard, D., Ohe, Y., Ramalingam, S. S., Ahn, M.-J., Kim, S.-W., Su, W.-C., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411817 · Cited by 2,116 · see citing works
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
Wu, Y.-L., Zhou, C., Hu, C.-P., Feng, J., Lu, S., Huang, Y., Li, W., Hou, M., Shi, J. H., Lee, K. Y., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70604-1 · Cited by 1,978 · see citing works
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
Giaccone, G., Herbst, R. S., Manegold, C., Scagliotti, G. V., Rosell, R., Miller, V. A., Natale, R. B., Schiller, J. H., von Pawel, J., Pluzanska, A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.001 · Cited by 1,712 · see citing works
Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2
Herbst, R. S., Giaccone, G., Schiller, J. H., Natale, R. B., Miller, V. A., Manegold, C., Scagliotti, G. V., Rosell, R., Oliff, I. A., Reeves, J. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.215 · Cited by 1,703 · see citing works
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
Bean, J., Brennan, C., Shih, J.-Y., Riely, G., Viale, A., Wang, L., Chitale, D., Motoi, N., Szoke, J., Broderick, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710370104 · Cited by 1,598 · see citing works
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer
Herbst, R. S., Prager, D., Hermann, R., Fehrenbacher, L., Johnson, B. E., Sandler, A., Kris, M. G., Tran, H. T., Klein, P., Li, X., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.840 · Cited by 1,490 · see citing works
Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology
Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Chirieac, L. R., D’Amico, T. A., DeCamp, M. M., Dilling, T. J., Dobelbower, M. C., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0050 · Cited by 1,305 · see citing works
Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer
Kosaka, T., Yatabe, Y., Endoh, H., Kuwano, H., Takahashi, T., & Mitsudomi, T. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2818 · Cited by 1,220 · see citing works
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Peters, S., Adjei, A. A., Gridelli, C., Reck, M., Kerr, K. M., & Felip, E. (2012) · Annals of Oncology · doi:10.1093/annonc/mds226 · Cited by 930 · see citing works
Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non–Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial
Gatzemeier, U., Pluzanska, A., Szczęsna, A., Kaukel, E., Roubec, J., Rosa, F. D., Milanowski, J., Karnicka-Mlodkowski, H., Pešek, M., Serwatowski, P., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.1474 · Cited by 875 · see citing works
Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors
Balak, M. N., Gong, Y., Riely, G. J., Somwar, R., Li, A. R., Zakowski, M. F., Chiang, A. C., Yang, G., Ouerfelli, O., Kris, M. G., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1570 · Cited by 823 · see citing works
Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
Jackman, D., Pao, W., Riely, G. J., Engelman, J. A., Kris, M. G., Jänne, P. A., Lynch, T., Johnson, B. E., & Miller, V. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.7049 · Cited by 793 · see citing works
First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung
Han, J.-Y., Park, K., Kim, S.-W., Lee, D. H., Kim, H. Y., Kim, H. T., Ahn, M. J., Yun, T., Ahn, J. S., Suh, C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.8456 · Cited by 736 · see citing works
Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)
Grothey, A. F., Sugrue, M. M., Purdie, D. M., Dong, W., Sargent, D. J., Hedrick, E. E., & Kozloff, M. F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3212 · Cited by 688 · see citing works
Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer
Weickhardt, A. J., Scheier, B., Burke, J. M., Gan, G., Lu, X., Bunn, P. A., Aisner, D. L., Gaspar, L. E., Kavanagh, B. D., Doebele, R. C., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182745948 · Cited by 684 · see citing works
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Reck, M., Popat, S., Reinmuth, N., Ruysscher, D. D., Kerr, K. M., & Peters, S. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu199 · Cited by 679 · see citing works
Self-citation
Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation
Oxnard, G. R., Arcila, M. E., Sima, C. S., Riely, G. J., Chmielecki, J., Kris, M. G., Pao, W., Ladanyi, M., & Miller, V. A. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2692 · Cited by 627 · see citing works
Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay
Arcila, M. E., Oxnard, G. R., Nafa, K., Riely, G. J., Solomon, S. B., Zakowski, M. F., Kris, M. G., Pao, W., Miller, V. A., & Ladanyi, M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2277 · Cited by 574 · see citing works
Non–Small Cell Lung Cancer, Version 6.2015
Ettinger, D. S., Wood, D. E., Akerley, W., Bazhenova, L. A., Borghaei, H., Camidge, D. R., Cheney, R. T., Chirieac, L. R., D’Amico, T. A., Demmy, T. L., et al. (2015) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2015.0071 · Cited by 478 · see citing works
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant Disease
Ohashi, K., Maruvka, Y. E., Michor, F., & Pao, W. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.3912 · Cited by 467 · see citing works
Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design
Chaft, J. E., Oxnard, G. R., Sima, C. S., Kris, M. G., Miller, V. A., & Riely, G. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1468 · Cited by 418 · see citing works
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
Soria, J.-C., Wu, Y.-L., Nakagawa, K., Kim, S.-W., Yang, J.-J., Ahn, M.-J., Wang, J., Yang, J. C.-H., Lu, Y., Atagi, S., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00121-7 · Cited by 413 · see citing works
Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis
Watanabe, S., Tanaka, J., Ota, T., Kondo, R., Tanaka, H., Kagamu, H., Ichikawa, K., Koshio, J., Baba, J., Miyabayashi, T., et al. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-1 · Cited by 392 · see citing works
Prospective Multicentric Randomized Phase III Study of Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors Comparing Interruption Versus Continuation of Treatment Beyond 1 Year: The French Sarcoma Group
Blay, J., Cesne, A. L., Ray-Coquard, I. L., Bui, B., Duffaud, F., Delbaldo, C., Adenis, A., Viens, P., Rios, M., Bompas, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.0183 · Cited by 392 · see citing works
New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer
Oxnard, G. R., Arcila, M. E., Chmielecki, J., Ladanyi, M., Miller, V. A., & Pao, W. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2571 · Cited by 355 · see citing works
Novel Targets in Non-Small Cell Lung Cancer: ROS1 and RET Fusions
Gainor, J. F., & Shaw, A. T. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0095 · Cited by 346 · see citing works
Local Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to EGFR Tyrosine Kinase Inhibitors
Yu, H. A., Sima, C. S., Huang, J. G., Solomon, S. B., Rimner, A., Paik, P. K., Pietanza, M. C., Azzoli, C. G., Rizvi, N. A., Krug, L. M., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31827e1f83 · Cited by 340 · see citing works
Development of Therapeutic Combinations Targeting Major Cancer Signaling Pathways
Yap, T. A., Omlin, A. G., & Bono, J. S. D. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.6418 · Cited by 328 · see citing works
Self-citation
Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial
Wu, Y.-L. L. C., Lee, J. S., Thongprasert, S., Yu, C., Zhang, L., Ladrera, G., Srimuninnimit, V., Sriuranpong, V., Sandoval-Tan, J., Zhu, Y., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70254-7 · Cited by 298 · see citing works
Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Everolimus
Riely, G. J., Kris, M. G., Zhao, B., Akhurst, T. J., Milton, D. T., Moore, E., Tyson, L. B., Pao, W. J., Rizvi, N. A., Schwartz, L. H., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0560 · Cited by 288 · see citing works
Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib
Jackman, D. M., Holmes, A. J., Lindeman, N., Wen, P. Y., Kesari, S., Borras, A. M., Bailey, C., de Jong, F., Jänne, P. A., & Johnson, B. E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.6126 · Cited by 260 · see citing works
First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer: The ASPIRATION Study
Park, K., Yu, C.-J., Kim, S.-W., Lin, M.-C., Sriuranpong, V., Tsai, C.-M., Lee, J.-S., Kang, J.-H., Chan, K. C. A., Perez-Moreno, P., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4921 · Cited by 229 · see citing works
High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib
Omuro, A. M. P., Kris, M. G., Miller, V. A., Franceschi, E., Shah, N. T., Milton, D. T., & Abrey, L. E. (2005) · Cancer · doi:10.1002/cncr.21033 · Cited by 227 · see citing works
Biological and clinical implications of EGFR mutations in lung cancer
Mitsudomi, T., Kosaka, T., & Yatabe, Y. (2006) · International Journal of Clinical Oncology · doi:10.1007/s10147-006-0583-4 · Cited by 216 · see citing works
Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib
Héon, S., Yeap, B. Y., Britt, G. J., Costa, D. B., Rabin, M. S., Jackman, D. M., & Johnson, B. E. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1588 · Cited by 216 · see citing works
Randomized, Placebo-Controlled, Phase II Study of Sequential Erlotinib and Chemotherapy As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer
Mok, T. S. K., Wu, Y.-L. L. C., Yu, C., Zhou, C., Chen, Y.-M., Zhang, L., Ignacio, J. G., Liao, M., Srimuninnimit, V., Boyer, M. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.5541 · Cited by 215 · see citing works
Efficacy of Erlotinib for Brain and Leptomeningeal Metastases in Patients with Lung Adenocarcinoma Who Showed Initial Good Response to Gefitinib
Katayama, T., Shimizu, J., Suda, K., Onozato, R., Fukui, T., Ito, S., Hatooka, S., Sueda, T., Hida, T., Yatabe, Y., et al. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181b62572 · Cited by 161 · see citing works
Phase II Study of Erlotinib in Advanced Non–Small-Cell Lung Cancer After Failure of Gefitinib
Cho, B. C., Im, C. K., Park, M. S., Kim, S. I., Chang, J., Park, J. P., Choi, H. J., Kim, Y. J., Shin, S. J., Sohn, J., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.4166 · Cited by 148 · see citing works
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
Schüler, M., Yang, J. C., Park, K., Kim, J., Bennouna, J., Chen, Y.-M., CHOUAID, C., de Marinis, F., Feng, J., Grossi, F., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv597 · Cited by 132 · see citing works
Chemotherapy With Erlotinib or Chemotherapy Alone in Advanced Non-Small Cell Lung Cancer With Acquired Resistance to EGFR Tyrosine Kinase Inhibitors
Goldberg, S. B., Oxnard, G. R., Digumarthy, S., Muzikansky, A., Jackman, D. M., Lennes, I. T., & Sequist, L. V. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0168 · Cited by 130 · see citing works
Association of Exon 19 and 21 EGFR Mutation Patterns with Treatment Outcome after First-Line Tyrosine Kinase Inhibitor in Metastatic Non–Small-Cell Lung Cancer
Lee, V. H.-F., Tin, V. P., Choy, T., Lam, K. O., Choi, C., Chung, L.-P., Tsang, J. W. H., Ho, P., Leung, D. K., Ma, E. S. K., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31829f684a · Cited by 125 · see citing works
Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials
Pujol, J.-L., Barlési, F., & Daurès, J. (2006) · Lung Cancer · doi:10.1016/j.lungcan.2005.11.001 · Cited by 124 · see citing works
Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment
Becker, A., Crombag, L., Heideman, D. A. M., Thunnissen, F. B., van Wijk, A. W., Postmus, P. E., & Smit, E. F. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.06.046 · Cited by 117 · see citing works
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Beyond Progressive Disease: A Retrospective Analysis for Japanese Patients with Activating EGFR Mutations
Nishie, K., Kawaguchi, T., Tamiya, A., Mimori, T., Takeuchi, N., Matsuda, Y., Omachi, N., Asami, K., Okishio, K., Atagi, S., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31826913f7 · Cited by 104 · see citing works
An Initial Report of a Radiation Dose-Escalation Trial in Patients with One to Five Sites of Metastatic Disease
Salama, J. K., Chmura, S. J., Mehta, N., Yenice, K. M., Stadler, W. M., Vokes, E. E., Haraf, D. J., Hellmän, S., & Weichselbaum, R. R. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0358 · Cited by 89 · see citing works
Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure
Shukuya, T., Takahashi, T., Naito, T., Kaira, R., Ono, A., Nakamura, Y., Tsuya, A., Kenmotsu, H., Murakami, H., Harada, H., et al. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.04.007 · Cited by 89 · see citing works
Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
Yokouchi, H., Yamazaki, K., Kinoshita, I., Konishi, J., Asahina, H., Sukoh, N., Harada, M., Akie, K., Ogura, S., Ishida, T., et al. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-51 · Cited by 85 · see citing works
Acquired Resistance to Targeted Therapies Against Oncogene-Driven Non–Small-Cell Lung Cancer: Approach to Subtyping Progressive Disease and Clinical Implications
Gandara, D. R., Li, T., Lara, P. N., Kelly, K. L., Riess, J. W., Redman, M. W., & Mack, P. C. (2013) · Clinical Lung Cancer · doi:10.1016/j.cllc.2013.10.001 · Cited by 83 · see citing works
Brain Metastases from NSCLC: Radiation Therapy in the Era of Targeted Therapies
Khalifa, J., Amini, A., Popat, S., Gaspar, L. E., & Finn, C. F. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.06.002 · Cited by 83 · see citing works
Self-citation
Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors
Nishino, M., Cardarella, S., Dahlberg, S. E., Jackman, D. M., Ramaiya, N. H., Hatabu, H., Rabin, M. S., Janne, P. A., & Johnson, B. E. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.11.007 · Cited by 73 · see citing works
Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib
Tartarone, A., Lazzari, C., Lerose, R., Conteduca, V., Improta, G., Zupa, A., Bulotta, A., Aieta, M., & Gregorc, V. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.05.020 · Cited by 62 · see citing works
Treatment of Advanced Non–Small-Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation or ALK Gene Rearrangement: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology
Gridelli, C., de Marinis, F., Cappuzzo, F., Maïo, M. D., Hirsch, F. R., Mok, T. S. K., Morgillo, F., Rosell, R., Spigel, D. R., Yang, J. C., et al. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2013.12.002 · Cited by 61 · see citing works
EGFR-tyrosine kinase inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced non-small cell lung cancer: A case–control study of overall survival
Faehling, M., Eckert, R., Kamp, T., Kuom, S., Griese, U., Sträter, J., Ott, G., & Spengler, W. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.02.010 · Cited by 44 · see citing works
Clinical Utility of Continuing Trastuzumab Beyond Brain Progression in HER-2–Positive Metastatic Breast Cancer
Metro, G., Sperduti, I., Russillo, M., Milella, M. S., Cognetti, F., & Fabi, A. (2007) · The Oncologist · doi:10.1634/theoncologist.12-12-1467 · Cited by 41 · see citing works
Continued treatment with gefitinib beyond progressive disease benefits patients with activating EGFR mutations
Asami, K., Okuma, T., Hirashima, T., Kawahara, M., Atagi, S., Kawaguchi, T., Okishio, K., Omachi, N., & Takeuchi, N. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.11.022 · Cited by 35 · see citing works
Living With Imperfection
Mok, T. S. K. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.8574 · Cited by 34 · see citing works
Algorithm for Codevelopment of New Drug-Predictive Biomarker Combinations: Accounting for Inter- and Intrapatient Tumor Heterogeneity
Gandara, D. R., Li, T., Lara, P. N., Mack, P. C., Kelly, K. L., Miyamoto, S., Goodwin, N. C., Beckett, L. A., & Redman, M. W. (2012) · Clinical Lung Cancer · doi:10.1016/j.cllc.2012.05.004 · Cited by 28 · see citing works
Treatment after the failure of gefitinib in patients with advanced or recurrent non-small cell lung cancer.
Maruyama, R., Wataya, H., Seto, T., & Ichinose, Y. (2009) · PubMed · Cited by 28 · see citing works
Epidermal Growth Factor Receptor Inhibitors plus Chemotherapy in Non–Small-Cell Lung Cancer: Biologic Rationale for Combination Strategies
Gandara, D. R., Davies, A. M., Gautschi, O. P., Mack, P. C., Lau, D. H., Lara, P. N., & Hirsch, F. R. (2007) · Clinical Lung Cancer · doi:10.3816/clc.2007.s.003 · Cited by 26 · see citing works
Continuous administration of EGFR-TKIs following radiotherapy after disease progression in bone lesions for non-small cell lung cancer.
Inomata, M., Shukuya, T., Takahashi, T., Ono, A., Nakamura, Y., Tsuya, A., Kenmotsu, H., Naito, T., Murakami, H., Harada, H., et al. (2011) · PubMed · Cited by 26 · see citing works
Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer
Halmos, B., Pennell, N. A., Fu, P., Saad, S., Gadgeel, S. M., Otterson, G. A., Mekhail, T. M., Snell, M., Kuebler, J. P., Sharma, N., et al. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0136 · Cited by 22 · see citing works
EGFR-Mutant Lung Adenocarcinomas Treated First-Line with the Novel EGFR Inhibitor, XL647, Can Subsequently Retain Moderate Sensitivity to Erlotinib
Chmielecki, J., Pietanza, M. C., Aftab, D. T., Shen, R., Zhao, Z., Chen, X., Hutchinson, K. E., Viale, A. J., Kris, M. G., Stout, T. J., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31823c5aee · Cited by 21 · see citing works
Gefitinib plus paclitaxel after failure of gefitinib in non-small cell lung cancer initially responding to gefitinib.
Shukuya, T., Takahashi, T., Tamiya, A., Ono, A., Igawa, S., Nakamura, Y., Tsuya, A., Murakami, H., Naito, T., Kaira, K., et al. (2009) · PubMed · Cited by 21 · see citing works
Oligometastatic Disease at Presentation or Recurrence for Nonsmall Cell Lung Cancer
Gomez, D. R., Niibe, Y., & Chang, J. Y. (2012) · Pulmonary Medicine · doi:10.1155/2012/396592 · Cited by 20 · see citing works
Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance
Wu, W.-S., & Chen, Y. (2014) · Journal of Personalized Medicine · doi:10.3390/jpm4030297 · Cited by 14 · see citing works
Rationale and Study Design of the IRENE-Trial (NVALT-16): A Phase II Trial to Evaluate Iressa Rechallenge in Advanced NSCLC Patients With an Activating EGFR Mutation Who Responded to an EGFR-TKI Used As First-Line or Previous Treatment
Kuiper, J. L., Heideman, D. A. M., Würdinger, T., Grünberg, K., Groen, H. J. M., & Smit, E. F. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.07.008 · Cited by 13 · see citing works

Flagged first, then by citations

Sorted by citations

Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR -Mutant NSCLC
Le, X., Puri, S., Negrao, M. V., Nilsson, M. B., Robichaux, J., Boyle, T., Hicks, J. K., Lovinger, K. L., Roarty, E., Rinsurongkawong, W., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1542 · Cited by 387 · see citing works
Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer
Blumenthal, G. M., Gong, Y., Kehl, K. L., Mishra-Kalyani, P. S., Goldberg, K. B., Khozin, S., Kluetz, P. G., Oxnard, G. R., & Pazdur, R. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz060 · Cited by 171 · see citing works
The Dandelion Dilemma Revisited for Oligoprogression: Treat the Whole Lawn or Weed Selectively?
Patel, P. H., Palma, D. A., McDonald, F., & Tree, A. C. (2019) · Clinical Oncology · doi:10.1016/j.clon.2019.05.015 · Cited by 115 · see citing works
Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings
Harvey, R. D., Adams, V. R., Beardslee, T., & Medina, P. (2020) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155220931926 · Cited by 115 · see citing works
Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers
Choudhury, N. J., Marra, A., Sui, J. S. Y., Flynn, J. R., Yang, S., Falcon, C. J., Selenica, P., Schoenfeld, A. J., Rekhtman, N., Gomez, D. R., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.11.022 · Cited by 116 · see citing works
Src-dependent EGFR transactivation regulates lung inflammation via downstream signaling involving ERK1/2, PI3Kδ/Akt and NFκB induction in a murine asthma model
El‐Hashim, A. Z., Khajah, M. A., Renno, W. M., Babyson, R. S., Uddin, M., Benter, I. F., Ezeamuzie, C. I., & Akhtar, S. (2017) · Scientific Reports · doi:10.1038/s41598-017-09349-0 · Cited by 77 · see citing works
Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer
Dolly, S. O., Collins, D. C., Sundar, R., Popat, S., & Yap, T. A. (2017) · Drugs · doi:10.1007/s40265-017-0732-2 · Cited by 57 · see citing works
Self-citation
Detection of ROS1 rearrangement in non-small cell lung cancer: current and future perspectives
Rossi, G., Jocollé, G., Conti, A., Tiseo, M., Marino, F. Z., Donati, G., Franco, R., Bono, F., Barbisan, F., & Facchinetti, F. (2017) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s120172 · Cited by 53 · see citing works
Treatment Strategies for Non-Small Cell Lung Cancer with Common EGFR Mutations: A Review of the History of EGFR TKIs Approval and Emerging Data
Marin-Acevedo, J. A., Pellini, B., Kimbrough, E. O., Hicks, J. K., & Chiappori, A. (2023) · Cancers · doi:10.3390/cancers15030629 · Cited by 49 · see citing works
Comprehensive Analysis of Cancer-Proteogenome to Identify Biomarkers for the Early Diagnosis and Prognosis of Cancer
Shukla, H. D. (2017) · Proteomes · doi:10.3390/proteomes5040028 · Cited by 40 · see citing works
Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study
Ji, J., Aredo, J. V., Piper‐Vallillo, A. J., Huppert, L. A., Rotow, J. K., Husain, H., Stewart, S., Cobb, R. G., Wakelee, H. A., Blakely, C. M., et al. (2023) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100459 · Cited by 38 · see citing works
Oncogenic driver mutations, treatment, and EGFR-TKI resistance in a Caucasian population with non-small cell lung cancer: survival in clinical practice
Faehling, M., Schwenk, B., Kramberg, S., Eckert, R., Volckmar, A., Stenzinger, A., & Sträter, J. (2017) · Oncotarget · doi:10.18632/oncotarget.20857 · Cited by 34 · see citing works
First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression
Schüler, M., Tan, E.-H., O'Byrne, K. J., Zhang, L., Boyer, M. J., Mok, T. S. K., Hirsh, V., Yang, J. C., Lee, K. H., Lü, S., et al. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02862-x · Cited by 35 · see citing works
Novel approaches against epidermal growth factor receptor tyrosine kinase inhibitor resistance
Heydt, C., Michels, S. Y. F., Thress, K. S., Bergner, S., Wolf, J., & Buettner, R. (2018) · Oncotarget · doi:10.18632/oncotarget.24624 · Cited by 27 · see citing works
Tissue is the issue and tissue competition. Re‐biopsy for mutation T790: where and why?
Zarogoulidis, P., Gaga, M., Huang, H., Darwiche, K., Rapti, A., & Hohenforst‐Schmidt, W. (2017) · Clinical and Translational Medicine · doi:10.1186/s40169-017-0135-8 · Cited by 24 · see citing works
Comparison of Epidermal Growth Factor Receptor Gene Mutations Identified Using Pleural Effusion and Primary Tumor Tissue Samples in Non–Small Cell Lung Cancer
Liu, N., Sun, R., Du, J., Dong, Q., Fan, C., Li, Q., Wang, E., & Liu, Y. (2017) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000543 · Cited by 22 · see citing works
Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer
Facchinetti, F., Proto, C., Minari, R., Garassino, M. C., & Tiseo, M. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_16 · Cited by 21 · see citing works
Palbociclib overcomes afatinib resistance in non-small cell lung cancer
Nie, H., Zhou, X., Du, S., Nie, C., Zhang, X., & Huang, J. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.10.170 · Cited by 21 · see citing works
Systemic Therapy for Oligoprogression in Patients with Metastatic NSCLC Harboring Activating EGFR Mutations
Rossi, A., & Galetta, D. (2022) · Cancers · doi:10.3390/cancers14030832 · Cited by 20 · see citing works
The components and regulation of the Hippo pathway and its relationships with the progression and treatment of Non-small cell lung cancer (NSCLC)
Feng, Y., Gan, X., Rong, X., & Han, Q. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03946-0 · Cited by 17 · see citing works
Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer: how to treat and when?
Schoenmaekers, J. J. A. O., Paats, M. S., Dingemans, A. C., & Hendriks, L. E. L. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-459 · Cited by 13 · see citing works
Efficacy of lorlatinib in lung carcinomas carrying distinct ALK translocation variants: The results of a single-center study
Orlov, S., Iyevleva, A. G., Filippova, E. A., Lozhkina, A. M., Odintsova, S. V., Sokolova, T. N., Mitiushkina, N. V., Tiurin, V. I., Преображенская, Е. В., Romanko, A. A., et al. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101121 · Cited by 12 · see citing works
N6‐Methyladenosine Reader YTHDF2 Enhances Non‐Small‐Cell Lung Cancer Cell Proliferation and Metastasis through Mediating circ_SFMBT2 Degradation
Xu, J., Shang, Y., Qin, X., Gai, Y., Cai, F., Xiao, H., Zhou, C., Fu, Y., & Ge, X. (2022) · Contrast Media & Molecular Imaging · doi:10.1155/2022/1087622 · Cited by 12 · see citing works
Targeted methods for molecular characterization of EGFR mutational profile in lung cancer Moroccan cohort
Kaanane, H., Attar, H. E., Louahabi, A., Berradi, H., Idrissi, H. H., Khyatti, M., & Nadifi, S. (2019) · Gene · doi:10.1016/j.gene.2019.04.044 · Cited by 11 · see citing works
An Observatory for the MET Oncogene: A Guide for Targeted Therapies
Altintas, D. M., & Comoglio, P. M. (2023) · Cancers · doi:10.3390/cancers15184672 · Cited by 11 · see citing works
Early radiological response as predictor of overall survival in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor mutations
Coloma, C. S., Lorente, D., Palanca, S., Simarro, J., Mancheño, N., Sandoval, J., Lahoz, A., & Juan, Ó. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.02.30 · Cited by 8 · see citing works
Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21)
Mennitto, A., Zattarin, E., Maïo, M. D., Bimbatti, D., Giorgi, U. D., Buti, S., Santini, D., Casadei, C., Sorarù, M., Messina, C. G. M., et al. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2002688 · Cited by 8 · see citing works
Utility of stereotactic ablative radiotherapy/stereotactic body radiation therapy in the setting of oligometastatic non-small cell lung cancer
Song, A. J., & Lü, B. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.01.22 · Cited by 7 · see citing works
Results of switchback from ranibizumab to aflibercept in patients with exudative age-related macular degeneration
Koike, N., Otsuji, T., Tsumura, A., Miki, K., Sakai, Y., Nishimura, T., & Takahashi, K. A. (2019) · Clinical ophthalmology · doi:10.2147/opth.s206910 · Cited by 6 · see citing works
An mTOR feedback loop mediates the ‘flare’ (‘rebound’) response to MET tyrosine kinase inhibition
Altintas, D. M., Cerqua, M., Laurentiis, A. D., Trusolino, L., Boccaccio, C., & Comoglio, P. M. (2023) · Scientific Reports · doi:10.1038/s41598-023-28648-3 · Cited by 6 · see citing works
Long-term survival with erlotinib in advanced lung adenocarcinoma harboring synchronous EGFR G719S and KRAS G12C mutations
Ricciuti, B., Baglivo, S., Ludovini, V., Sidoni, A., Metro, G., Brambilla, M., Siggillino, A., Reda, M. S., Rebonato, A., Maiettini, D., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.04.002 · Cited by 6 · see citing works
The expression of Nanog protein and fibroblast growth factor-inducible molecule 14 in patients with non-small cell lung cancer and their relationship with pathological characteristics and prognosis
Wang, Y., Zhou, P., Cui, C., He, X.-X., Bian, Y., & Wang, X. (2021) · Translational Cancer Research · doi:10.21037/tcr-21-724 · Cited by 6 · see citing works
Thirty-Day Mortality Following Systemic Anticancer Therapy: Evaluating Risk Factors Without Selection Bias in a Real-World, Population-Based Cohort From 2009 to 2019
Vesteghem, C., Brøndum, R. F., Mouritzen, M. T., Christensen, H. S., Bøgsted, M., Falkmer, S., & Poulsen, L. Ø. (2022) · Clinical Oncology · doi:10.1016/j.clon.2022.03.015 · Cited by 5 · see citing works
Afatinib for the First-Line Treatment of EGFR Mutation-Positive NSCLC in China: a Review of Clinical Data
Tu, H., & Wu, Y.-L. L. C. (2020) · Future Oncology · doi:10.2217/fon-2020-0320 · Cited by 4 · see citing works
ORIENT-31 as the Sakigake “Charging Samurai” Born of IMpower150 but Will MARIPOSA-2 IMPRESS in the “Meiji Modernization” of Post-3G EGFR TKI Progression?
Nagasaka, M., & Ou, S.-H. I. (2022) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s355503 · Cited by 3 · see citing works
Nursing Considerations for Patients Treated with Targeted Therapies
Goodwin, K. E., & Davies, M. J. (2019) · Springer eBooks · doi:10.1007/978-3-030-16550-5_9
30-day mortality of patients with advanced cancer: monitoring and machine learning models using extensive health data
Vesteghem, C. (2022) · doi:10.54337/aau468602374
Not all progression is equal
Venkateswaran, S., Mantena, R. V., Willmann, J., Zhang, Y. H., Dee, E. C., & Iyengar, P. (2026) · Cancer · doi:10.1002/cncr.70311

Management of NSCLC Disease Progression After First-Line EGFR Tyrosine Kinase Inhibitors: What Are the Issues and Potential Therapies?
Califano, R., Romanidou, O., Mountzios, G., Landi, L. M., Cappuzzo, F., & Blackhall, F. H. (2016) · Drugs · doi:10.1007/s40265-016-0578-z · Cited by 16 · see citing works
Beyond EGFR TKI in EGFR-mutant Non-Small Cell Lung Cancer patients: Main challenges still to be overcome
Remón, J., Morán, T., Reguart, N., Majem, M., Carcereny, E., & LIANES, P. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.03.006 · Cited by 22 · see citing works
Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors
Chen, Q., Quan, Q., Ding, L., Hong, X., Zhou, N., Liang, Y., & Wu, H. (2015) · Oncotarget · doi:10.18632/oncotarget.4570 · Cited by 22 · see citing works
Radiotherapy with continued EGFR-TKIs for oligoprogressive disease in non-small cell lung cancer: A real-world study
Wu, F., Wu, S., & Hu, H. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy446.009 · Cited by 1 · see citing works
EGFR Mutation Positive Stage IV Non-Small-Cell Lung Cancer: Treatment Beyond Progression
Assche, K. V., Ferdinande, L., Lievens, Y. N., Vandecasteele, K., & Surmont, V. F. M. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00350 · Cited by 19 · see citing works

Authors: Yap, T. A., Macklin-Doherty, A., & Popat, S.
Affiliations: Institute of Cancer Research (GB)
Royal Marsden Hospital (GB)
Corresponding author: Popat, Sanjay
ORCID: Yap, Timothy A.
Macklin-Doherty, Aislinn
Popat, Sanjay
Venue: European Journal of Cancer
Publisher: Elsevier BV
Published: 2017-01
Volume: 70
Pages: 12-21
ISSN: 0959-8049 (ISSN-L)
DOI: 10.1016/j.ejca.2016.10.014
OpenAlex: W2554087867
Cited by: 38
References: 84
Citations by year: 2026: 1 · 2025: 1 · 2023: 4 · 2022: 6 · 2021: 3 · 2020: 3 · 2019: 6 · 2018: 6 · 2017: 8
FWCI: 1.16
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: European Journal of Cancer (publishedVersion)
PubMed (publishedVersion)
Funders: NIHR Biomedical Research Centre at The Royal Marsden
ICR
Academy of Medical Sciences
British Lung Foundation
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords: EGFR-mutant non-small cell lung cancer, EGFR tyrosine kinase inhibitors, disease progression, drug holidays, oligometastatic disease, central nervous system metastasis, liquid biopsy, precision medicine
MeSH terms: Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Disease Progression, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, Molecular Targeted Therapy, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancer

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks